Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines
Article first published online: 25 JUN 2002
Volume 90, Issue 1, pages 113–117, July 2002
How to Cite
Hong, J.H., Lee, E., Hong, J., Shin, Y.J. and Ahn, H. (2002), Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU International, 90: 113–117. doi: 10.1046/j.1464-410X.2002.02799.x
- Issue published online: 25 JUN 2002
- Article first published online: 25 JUN 2002
- Accepted for publication 19 February 2002
- bladder cancer;
- antisense oligonucleotide
Objective To determine the change of expression of Bcl2 in cisplatin-resistant bladder cancer cell lines and the reversibility of chemoresistance to cisplatin with antisense oligonucleotide against Bcl2, as higher expression of Bcl2 is associated with drug resistance in many different cancer cell lines.
Materials and methods In the cisplatin-resistant bladder tumour cell lines T24R1 and T24R2, the expression of Bcl2 was determined by reverse transcription-polymerase chain reaction and Western blot assay, and antisense oligonucleotide targeting of the Bcl2 coding sequence was administered with lipofectin.
Results The expression of Bcl2 mRNA and protein was greater in T24R1 and T24R2 cells than in the parent T24 cells. Short-term exposure to cisplatin up-regulated Bcl2 mRNA and protein expression in parent T24 cells. Treatment with antisense oligonucleotide down-regulated Bcl2 protein expression and significantly enhanced the cytotoxicity of cisplatin.
Conclusions Up-regulation of Bcl2 protein expression might be one of the mechanisms of cisplatin resistance in bladder cancer cells, and antisense Bcl2 oligonucleotide may be helpful in chemotherapy for bladder cancer by reversing cisplatin resistance.